Vivos Therapeutics Inc (VVOS) Actualités

Form EFFECT - Notice of Effectiveness

Form 424B1 - Prospectus [Rule 424(b)(1)]

Form 8-K - Current report

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”...

Form S-1 - General form for registration of securities under the Securities Act of 1933

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New...

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

LITTLETON, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Vivos Therapeutics Closes $4 Million Private Placement

LITTLETON, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

LITTLETON, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Form 8-K - Current report

Vivos Therapeutics Announces Reverse Stock Split

LITTLETON, Colo., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

LITTLETON, Colo., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”...